Glaukos Corp. (GKOS)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · GKOS
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
and in the accompanying Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), except as shall be expressly set forth by specific reference in such filing.
and in the accompanying Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), except as shall be expressly set forth by specific reference in such filing.
Results of Operations and Financial Condition. On February 17, 2026, Glaukos Corporation (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information contained in this
Results of Operations and Financial Condition. On January 13, 2026, Glaukos Corporation (the “Company”) issued a press release announcing its preliminary, unaudited net sales results for the fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this
Results of Operations and Financial Condition. On October 29, 2025, Glaukos Corporation (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information contained in this
and in the accompanying Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), except as shall be expressly set forth by specific reference in such filing.
and in the accompanying Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), except as shall be expressly set forth by specific reference in such filing.
Results of Operations and Financial Condition. On February 20, 2025, Glaukos Corporation (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information contained in this
Regulation FD Disclosure. In a Current Report on Form 8-K filed with the Securities and Exchange Commission on December 3, 2024, Glaukos Corporation (the “Company”) previously disclosed that on December 2, 2024, it had entered into unwind agreements (the “Capped Call Unwind Agreements”) with certain financial institutions (the “Option Counterparties”) relating to a portion of the capped call transactions that were previously entered into by the Company with such Option Counterparties in conne…
Entry into a Material Definitive Agreement. On December 2, 2024, Glaukos Corporation (the “Company”) entered into unwind agreements with certain financial institutions (the “Option Counterparties”) relating to a portion of the capped call transactions (the “Capped Call Unwind Agreements”) that were previously entered into by the Company with such Option Counterparties in connection with the issuance of its 2.75% Convertible Senior Notes due 2027 (the “Notes”) in an aggregate principal amount…
Results of Operations and Financial Condition. On November 4, 2024, Glaukos Corporation (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information contained in this
Other Events. On October 4, 2024, Glaukos Corporation (the “Company”) issued a notice of redemption (the “Redemption Notice”) for all $57.5 million aggregate principal amount outstanding of its 2.75% Convertible Senior Notes due 2027 (the “Notes”), which were issued pursuant to an indenture dated June 11, 2020 (the “Indenture”) between the Company and Computershare Trust Company, National Association, as successor to Wells Fargo Bank, National Association, as trustee (the “Redemption”). Pursu…
Results of Operations and Financial Condition. On July 31, 2024, the Company issued the Earnings Release, a copy of which was furnished as Exhibit 99.1 to the Initial Report. On August 2, 2024, the Company filed with the SEC its Quarterly Report on Form 10-Q for its second quarter ended June 30, 2024 (its “Quarterly Report”). In preparing the final Quarterly Report, the Company, in consultation with its independent registered public accounting firm, concluded that, in connection with the exch…
and in the accompanying Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), except as shall be expressly set forth by specific reference in such filing.
Other Events. On June 28, 2024, the Company closed the transactions contemplated by the Exchange Agreements that it had previously announced on June 14, 2024 (the “ Exchange Transactions ”) with certain holders of the Company’s 2.75% Convertible Senior Notes due 2027 (the “ Existing Convertible Notes ”). In the Exchange Transactions, the holders exchanged $230,000,000 in aggregate principal amount of the Existing Convertible Notes for consideration consisting of an aggregate of 4,253,423 shar…
Unregistered Sales of Equity Securities. The disclosure under
Unregistered Sales of Equity Securities. The disclosure under
The filing describes the adoption of an equity compensation plan, which is a non-management matter mis-filed under Item 5.02.
and in the accompanying Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), except as shall be expressly set forth by specific reference in such filing.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.